Funding for COVID-19 Vaccines: An Overview [December 15, 2020]   [open pdf - 642KB]

From the Document: "On December 11, 2020, the U.S. Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for Pfizer/BioNTech's Coronavirus Disease 2019 (COVID-19) vaccine. Several other COVID-19 vaccines are currently in clinical trials or under review; additional vaccines may become available by the end of 2020. Moderna has announced preliminary Phase 3 results and is under EUA consideration. As a part of Operation Warp Speed (OWS)--the Trump Administration's COVID-19 medical countermeasure initiative led by the Department of Health and Human Services (HHS) and the Department of Defense (DOD)--the U.S. government has entered into several contracts with vaccine manufacturers to purchase hundreds of millions of doses (including Pfizer/BioNTech and Moderna's vaccine) and has also supported manufacturing and procurement of related supplies. Other OWS vaccine efforts include planning and implementation of a nationwide immunization program, public awareness, and vaccine data tracking, among others. OWS has thus far been financed largely by emergency funding provided in the coronavirus supplemental appropriations acts. To date, not much supplemental funding has been appropriated 'specifically' for COVID-19 vaccine-related efforts. Instead, funding has been provided to several accounts that 'may' be used toward relevant activities. [...] This Insight provides overviews of such appropriations for selected vaccine-related activities and available information on allocations and obligations. It does not address health care financing issues related to vaccine administration."

Report Number:
CRS Insight, IN11556
Public Domain
Retrieved From:
Congressional Research Service: https://crsreports.congress.gov/
Media Type:
Help with citations